UBS Initiates Coverage On Tectonic Therapeutic with Neutral Rating, Announces Price Target of $26
UBS analyst Alice Nettleton initiates coverage on Tectonic Therapeutic (NASDAQ:TECX) with a Neutral rating and announces Price Target of $26.
Stocks · News reference
Wells Fargo analyst Tiago Fauth maintains Tectonic Therapeutic (NASDAQ:TECX) with a Overweight and lowers the price target from $101 to $93.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
UBS analyst Alice Nettleton initiates coverage on Tectonic Therapeutic (NASDAQ:TECX) with a Neutral rating and announces Price Target of $26.
Filed: 2026-09-29 AccNo: 0001193125-26-407823 Size: 171 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Tectonic Therapeutic (NASDAQ:TECX) reported quarterly losses of $(1.18) per share which beat the analyst consensus estimate of $(1.37) by 13.87 percent. This is a 10.28 percent decrease over losses of $(1.07) per share